Institute for Glycomics, Griffith University, Queensland, Australia Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04415424
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Institute for Glycomics, Griffith University, Queensland, Australia

Active Ingredients

Drugs in Phase 3 Trials (1)

Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Gonorrhea (Phase 3)

Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1